RxDoctor Payments Data

Angela Wood

Psychiatric/Mental Health · Lebanon, TNNPI 1053387977

Payments from drug & device makers

$685in general payments, 2019–2025

Across 29 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$137
  • Lundbeck LLC$110
  • Takeda Pharmaceuticals U.S.A., Inc.$81
  • Otsuka America Pharmaceutical, Inc.$75
  • Neurocrine Biosciences, Inc.$65
  • Vanda Pharmaceuticals Inc.$55
  • plus $162 from 5 others

What the payments were for

  • Food & beverage$685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$685 in reported general payments places this provider in the 50th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$4,412
Medicare patients
12
Services billed
45

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole13$18,434
TrintellixVortioxetine Hydrobromide13$9,293
Desvenlafaxine Succinate ErDesvenlafaxine Succinate24$4,590
Clomipramine Hcl12$2,393
Duloxetine Hcl32$768
Bupropion XlBupropion Hcl32$716
Aripiprazole11$643
Vilazodone Hcl12$551
Quetiapine Fumarate24$391
Trazodone Hcl34$315
Buspirone Hcl22$313
Clonazepam65$296
Lamotrigine41$263
Mirtazapine18$212
Sertraline Hcl13$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$75$18,43413 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$81$9,29313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Lebanon

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →